 | | | | |
| |  | |  | | |
| |
 |
| PRIME NEWS | |
|
 |
|
|
Cerus is to acquire BioOne's commercialization rights for the Intercept blood system, in lieu of approximately 1,170,000 shares in common stock
|
|
|
|
|
|
|
|
|
Japanese drug giant Daiichi Sankyo has filed for approval in Japan to manufacture and market AMG 162 (Denosumab), a gene recombinant drug for bone disorders stemming from bone metastases
|
|
|
|
|
|
|
| | | 
BioSpectrum Japan is uniquely positioned as a specialized information platform for Japanese medical technology articles. It brings to you comprehensive coverage and useful Japan medical news in the areas of pharmaceuticals industry in Japan, Japanese medical technology, Japan medical devices and Biotech.
| | | | |  | |  | | |
|
|
|
|
|
|
|
|
|
|
 |
|
 |
|
|
|
 |
PEOPLE |
 |
|
|
|
Hospira CEO to quit
|
|
| Hospira has announced that Mr Christopher B Begley, chairman and CEO, has indicated his intent to retire from the CEO position |
|
|
|
|
|
GSK Japan gets new President
|
|
| GlaxoSmithKline has appointed Mr Philippe Fauchet as the President of GSK Japan. Mr Fauchet joins GSK from Sanofi Aventis where he was Senior Vice President, Business Development |
|
|
|
|
|
|
 |
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|  | |  | | | | |  | |  |
|
|
|
| | | | | | | | |
